Feb. 14, 2018 13:00 UTC 50 Premier U.S. Centers Adopt Sentinel Device in First Phase of Commercial Launch More Than 5,500 Patients Protected Worldwide Only Commercially Available TAVR Cerebral Protection Device in U.S., Europe and Asia Stacy Enxing Seng Joins Company’s Board of Directors SANTA ROSA, Calif.–(BUSINESS WIRE)– Since FDA […]
Other News
FDA Permits Marketing of Clinical Decision Support Software for Alerting Providers of a Potential Stroke in Patients
SILVER SPRING, Md., Feb. 13, 2018 /PRNewswire-USNewswire/ — Today, the U.S. Food and Drug Administration permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients. A stroke is […]
Avinger Announces Pricing of $18M Underwritten Public Offering
Secured Lenders Convert $38 Million of Debt into Equity REDWOOD CITY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) — Avinger, Inc.(NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross […]
Abiomed Wins Approval for Expanded FDA Indication for High Risk PCI Procedures
Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures DANVERS, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) — Abiomed(Nasdaq:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced that it has received an expanded U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the […]
Novoheart Signs Agreement with Sumocor to Develop Novel Therapeutics for Heart Failure
VANCOUVER, BRITISH COLUMBIA — (Marketwired) — Feb 14, 2018 — Novoheart(“Novoheart” or the “Company”) (TSX VENTURE: NVH), through its wholly owned US subsidiary, has entered into a commercial agreement with Sumocor LLC(“Sumocor”), a biotech company based in New York City that is focused on the development of therapeutics for cardiovascular diseases. Pursuant to […]
MyoKardia Begins Patient Dosing in Phase Ib Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
Topline Results from First-in-Human Phase 1 Study of MYK-491 in Healthy Volunteers Demonstrated Tolerability and Increased Contractility SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) —MyoKardia (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that dosing has commenced in […]
Surmodics to Host Virtual Annual Meeting of Shareholders
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)– SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 21, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting. Gary Maharaj, chief executive officer, and Sue Knight, chair of the board, will provide […]
Abiomed Announces Peripartum and Postpartum Cardiomyopathy Approval and Women’s Initiative for Heart Recovery
DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) — Abiomed(NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the launch of a new indication and Women’s Initiative focused on heart recovery education and awareness. This Women’s Initiative is in conjunction with the Company’s expanded FDA approval for cardiogenic […]
Global Heart Valve Devices Market 2017-2025 Size, Market Share, Application Analysis, Growth Trends, and Key Players – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Heart Valve Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025” report has been added to ResearchAndMarkets.com’s offering. The global heart valve devices market was valued at US$ 4,945 Mn in 2016, and is expected to reach US$ 13,377.9 Mn […]
Neovasc to Present at LEERINK Partners 7th Annual Global Healthcare Conference
VANCOUVER, Feb. 12, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present at the LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14th at 2:30 pm ET at the Lotte New York Palace in New York City. A live […]



